GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » ROIC %

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) ROIC % : -23.74% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Phoenix Biotech Acquisition ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Phoenix Biotech Acquisition's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2023 was -23.74%.

As of today (2024-06-08), Phoenix Biotech Acquisition's WACC % is 10.17%. Phoenix Biotech Acquisition's ROIC % is -10.30% (calculated using TTM income statement data). Phoenix Biotech Acquisition earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Phoenix Biotech Acquisition ROIC % Historical Data

The historical data trend for Phoenix Biotech Acquisition's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phoenix Biotech Acquisition ROIC % Chart

Phoenix Biotech Acquisition Annual Data
Trend Dec21 Dec22
ROIC %
- -25.74

Phoenix Biotech Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.09 4.47 -9.21 -56.98 -23.74

Competitive Comparison of Phoenix Biotech Acquisition's ROIC %

For the Shell Companies subindustry, Phoenix Biotech Acquisition's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phoenix Biotech Acquisition's ROIC % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Phoenix Biotech Acquisition's ROIC % distribution charts can be found below:

* The bar in red indicates where Phoenix Biotech Acquisition's ROIC % falls into.



Phoenix Biotech Acquisition ROIC % Calculation

Phoenix Biotech Acquisition's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-2.905 * ( 1 - -868.12% )/( (178.881 + 39.635)/ 2 )
=-28.123886/109.258
=-25.74 %

where

Phoenix Biotech Acquisition's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2023 is calculated as:

ROIC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-1.72 * ( 1 - -8.44% )/( (10.769 + 4.946)/ 2 )
=-1.865168/7.8575
=-23.74 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phoenix Biotech Acquisition  (NAS:PBAX) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Phoenix Biotech Acquisition's WACC % is 10.17%. Phoenix Biotech Acquisition's ROIC % is -10.30% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Phoenix Biotech Acquisition ROIC % Related Terms

Thank you for viewing the detailed overview of Phoenix Biotech Acquisition's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
2201 Broadway, Suite 705, Oakland, CA, USA, 94612
Website
Phoenix Biotech Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company intends to pursue an acquisition opportunity in any business, industry, sector or geographical location, industries that complement management team's background, and to capitalize on the ability of management team to identify and acquire a business in the healthcare or healthcare related industries in the United States and Europe.
Executives
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kathleen Laporte director
Christopher B Ehrlich director, 10 percent owner, officer: CEO and and Secretary 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Douglas Fisher officer: President 587 PATROL RD, WOODSIDE CA 94062
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Phoenix Biotech Sponsor, Llc 10 percent owner 2001 MARKET STREET, SUITE 3400, PHILADELPHIA PA 19103